modelD06AX01
Extends from Pharmacokinetic.Models.PK_1C_enteral.
Information
| name: | FusidicAcid | |
| ATC code: | D06AX01 | route: | oral |
| compartments: | 1 | |
| dosage: | 500 | mg |
| volume of distribution: | 10.7 | L |
| clearance: | 4.0 | L/h |
| other parameters in model implementation | ||
Fusidic acid is a steroidal antibiotic mainly used to treat skin and soft tissue infections caused by Staphylococcus aureus, including methicillin-resistant Staphylococcus aureus (MRSA). It is approved and widely used in topical, oral, and intravenous formulations, particularly in Europe and some other countries, although it is less commonly used in the United States.
Pharmacokinetics
Pharmacokinetic parameters reported for healthy adult volunteers after single oral administration.
References
Bulitta, JB, et al., & Ambrose, PG (2013). Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. Antimicrobial agents and chemotherapy 57(1) 498–507. DOI:10.1128/AAC.01354-12 PUBMED:https://pubmed.ncbi.nlm.nih.gov/23147726
Marsot, A, et al., & Blin, O (2017). Population pharmacokinetics of rifampicin in adult patients with osteoarticular infections: interaction with fusidic acid. British journal of clinical pharmacology 83(5) 1039–1047. DOI:10.1111/bcp.13178 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27813241
Marsot, A, et al., & Guilhaumou, R (2020). Evaluation of current dosing guidance for oral rifampicin treatment in adult patients with osteoarticular infections. British journal of clinical pharmacology 86(11) 2319–2324. DOI:10.1111/bcp.14319 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32330996
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)